Key Points • Only 40% of intolerance AEs in cohort 1 (ibrutinib intolerance) and 28% in cohort 2 (acalabrutinib intolerance) recurred with zanubrutinib.• After switching to zanubrutinib, 71% of patients… Click to show full abstract
Key Points • Only 40% of intolerance AEs in cohort 1 (ibrutinib intolerance) and 28% in cohort 2 (acalabrutinib intolerance) recurred with zanubrutinib.• After switching to zanubrutinib, 71% of patients in cohort 1 and 63% in cohort 2 maintained or had improved clinical benefit from treatment.
Keywords:
tolerated effective;
ibrutinib;
effective patients;
patients cll;
well tolerated;
zanubrutinib well
Journal Title: Blood Advances
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Blood Advances
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!